---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Incidence"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Incidence. Topics: Five-year incidence of AHI of at least 10 and at least 15 in a US community cohort (Cleveland Family Study, in-home sleep studies); Weight change and incident moderate-to-severe sleep-disordered breathing, AHI of 15 or more (Wisconsin Sleep Cohort, 4-year intervals); Five-year progression of the respiratory disturbance index with weight change (Sleep Heart Health Study); Predictors of five-year change in the respiratory disturbance index (Cleveland Family Study); 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/incidence"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of Obstructive sleep apnea

<a id="topic-2.2.1.2.1-1"></a>

### Five-year incidence of AHI of at least 10 and at least 15 in a US community cohort (Cleveland Family Study, in-home sleep studies)

> “Sleep-disordered breathing was defined by an AHI of at least 10 (mild to moderate) or of at least 15 (moderate).”
> “Forty-seven (16%) of 286 eligible participants, (95% confidence interval [CI], 13%-21%) had a second-study AHI of at least 10 and 29 (10%) participants (95% CI, 7%-14%) had a second-study AHI result of at least 15.”
> “The 5-year incidence is about 7.5% for moderately severe SDB and 16% (or less) for mild to moderately severe SDB.”
> “Predominance in men diminishes with increasing age, and by age 50 years, incidence rates among men and women are similar.”

Source: [Tishler et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12734134/)

<a id="topic-2.2.1.2.1-2"></a>

### Weight change and incident moderate-to-severe sleep-disordered breathing, AHI of 15 or more (Wisconsin Sleep Cohort, 4-year intervals)

> “Relative to stable weight, a 10% weight gain predicted an approximate 32% (95% confidence interval [CI], 20%-45%) increase in the AHI.”
> “A 10% weight loss predicted a 26% (95% CI, 18%-34%) decrease in the AHI.”
> “A 10% increase in weight predicted a 6-fold (95% CI, 2.2-17.0) increase in the odds of developing moderate-to-severe SDB.”

Source: [Peppard et al. (2000b)](https://pubmed.ncbi.nlm.nih.gov/11122588/)

<a id="topic-2.2.1.2.1-3"></a>

### Five-year progression of the respiratory disturbance index with weight change (Sleep Heart Health Study)

> “Men were more likely to have an increase in Respiratory Disturbance Index (RDI) with a given increase in weight than were women, and this was not explained by differences in starting weight, waist circumference, age, or ethnicity.”
> “However, SDB progressed over time, even in those with stable weight.”

Source: [Newman et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16287771/)

<a id="topic-2.2.1.2.1-4"></a>

### Predictors of five-year change in the respiratory disturbance index (Cleveland Family Study)

> “Longitudinal change in the RDI varies nonuniformly with age, sex, and weight.”
> “Older heavier men may experience the highest rate of increase in RDI over time and, thus, may benefit most from prospective monitoring.”

Source: [Redline et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/14572123/)

<a id="topic-2.2.1.2.1-5"></a>

### Diagnosed incidence in English primary care and hospital records, 2010 to 2019 (ResMed-authored)

> “Included adults had ≥ 1 OSA code and ≥ 12 months’ medical records before/after OSA diagnosis.”
> “The incidence of OSA increased from 46.74 per 100,000 in 2010 to 91.04 per 100,000 in 2019, with an average of 65.06 per 100,000 person-years over the period.”
> “The overall diagnosed incidence of OSA was 65.06 per 100,000 person-years (95% CI, 64.57-65.54).”
> “M. D., A. G., and N. A. are employees of ResMed and are ResMed shareholders.”

Source: [Ali et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13419131/)

<a id="topic-2.2.1.2.1-6"></a>

### Diagnosed incidence in active-component US military members, 2004 to 2015

> “The study identified 223,731 incident cases of OSA with an overall incidence rate of 139.2 per 10,000 person-years, between 2004 and 2015.”
> “Rates increased more than 3-fold between 2004 and 2015.”

Source: [Rogers et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27792352/)

<a id="topic-2.2.1.2.1-7"></a>

### Incidence of physician-reported sleep apnea after GLP-1 or dual agonist initiation in adults with obesity or type 2 diabetes (TriNetX records)

> “We identified adult patients with obesity and/or type 2 diabetes mellitus never prescribed GLP-1 or dual agonist therapy (reference arm) and those new initiators of these medications.”
> “Overall, GLP-1/dual agonists were associated with a 54% lower incidence of PRSA (HR, 0.46 [95% CI, 0.45-0.49]).”

Source: [Prado et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41915565/)

<a id="topic-2.2.1.2.1-8"></a>

### Absence of US incidence data in a national projection model (ResMed-funded)

> “Given the scarcity of data for obstructive sleep apnoea incidence in the USA, prevalence was used as a proxy to determine incidence by sex and age group.”
> “This study was funded by Resmed.”

Source: [Boers et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12674968/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
